

Erika Cecchin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1205408/publications.pdf>

Version: 2024-02-01

95
papers

3,057
citations

186265

28
h-index

182427

51
g-index

100
all docs

100
docs citations

100
times ranked

4153
citing authors

#	ARTICLE	IF	CITATIONS
1	The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 3061-3068.	1.6	328
2	Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 341-358.	4.7	240
3	Predictive Role of the <i>UGT1A1</i> , <i>UGT1A7</i> , and <i>UGT1A9</i> Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and Irinotecan. <i>Journal of Clinical Oncology</i> , 2009, 27, 2457-2465.	1.6	216
4	Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 866-871.	1.6	156
5	Development and validation of a microRNA-based signature (MiROvar) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. <i>Lancet Oncology</i> , The, 2016, 17, 1137-1146.	10.7	97
6	Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy. <i>Drug Resistance Updates</i> , 2015, 20, 39-70.	14.4	83
7	Clinical validity of a <i>DPYD</i> -based pharmacogenetic test to predict severe toxicity to fluoropyrimidines. <i>International Journal of Cancer</i> , 2015, 137, 2971-2980.	5.1	70
8	Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2019, 25, 3870-3896.	3.3	70
9	A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. <i>Pharmacogenomics Journal</i> , 2013, 13, 403-409.	2.0	66
10	Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy. <i>Pharmacogenomics Journal</i> , 2011, 11, 214-226.	2.0	63
11	Effect of <i>TP53 Arg72Pro</i> and <i>MDM2 SNP309</i> Polymorphisms on the Risk of High-Grade Osteosarcoma Development and Survival. <i>Clinical Cancer Research</i> , 2009, 15, 3550-3556.	7.0	62
12	Refining the <i>UGT1A</i> Haplotype Associated with Irinotecan-Induced Hematological Toxicity in Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Irinotecan-Based Regimens. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 345, 95-101.	2.5	58
13	Sex Disparities in Efficacy in COVID-19 Vaccines: A Systematic Review and Meta-Analysis. <i>Vaccines</i> , 2021, 9, 825.	4.4	57
14	New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. <i>Drug Resistance Updates</i> , 2020, 51, 100702.	14.4	53
15	Ubiquitous Pharmacogenomics (U-PCx): The Time for Implementation is Now. An Horizon2020 Program to Drive Pharmacogenomics into Clinical Practice. <i>Current Pharmaceutical Biotechnology</i> , 2017, 18, 204-209.	1.6	51
16	Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 549-557.	1.5	49
17	Estimating the Effectiveness of <i>DPYD</i> Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of Chemotherapy-Induced Toxicity. <i>American Journal of Human Genetics</i> , 2019, 104, 1158-1168.	6.2	43
18	Genetic Diversity of the KIR/HLA System and Outcome of Patients with Metastatic Colorectal Cancer Treated with Chemotherapy. <i>PLoS ONE</i> , 2014, 9, e84940.	2.5	40

#	ARTICLE	IF	CITATIONS
19	The Genotype for <i>DPYD</i> Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 994-1002.	4.7	39
20	ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 573-583.	1.5	37
21	Pharmacogenomics and Personalized Medicine. <i>Genes</i> , 2020, 11, 679.	2.4	37
22	Pharmacogenetics of Irinotecan. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2003, 3, 225-237.	7.0	36
23	Carboxylesterase Isoform 2 mRNA Expression in Peripheral Blood Mononuclear Cells Is a Predictive Marker of the Irinotecan to SN38 Activation Step in Colorectal Cancer Patients. <i>Clinical Cancer Research</i> , 2005, 11, 6901-6907.	7.0	34
24	CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6350.	4.1	34
25	MTHFR polymorphisms in gastric cancer and in first-degree relatives of patients with gastric cancer. <i>Tumor Biology</i> , 2010, 31, 23-32.	1.8	32
26	Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine. <i>Pharmacogenomics</i> , 2016, 17, 1547-1571.	1.3	31
27	Cost Evaluation of Irinotecan-Related Toxicities Associated With the <i>UGT1A1*28</i> Patient Genotype. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 123-130.	4.7	31
28	HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment. <i>PLoS ONE</i> , 2015, 10, e0144000.	2.5	31
29	Nuclear receptors and drug metabolism for the personalization of cancer therapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 291-306.	3.3	29
30	Thymidylate synthetase mRNA levels are increased in liver metastases of colorectal cancer patients resistant to fluoropyrimidine-based chemotherapy. <i>BMC Cancer</i> , 2004, 4, 11.	2.6	28
31	Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation. <i>Drug Resistance Updates</i> , 2018, 39, 18-40.	14.4	28
32	Pharmacogenetics of the nuclear hormone receptors: the missing link between environment and drug effects?. <i>Pharmacogenomics</i> , 2013, 14, 2035-2054.	1.3	27
33	SNCA 3'UTR genetic variants in patients with Parkinson's disease and REM sleep behavior disorder. <i>Neurological Sciences</i> , 2017, 38, 1233-1240.	1.9	27
34	Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study. <i>Pharmacogenetics and Genomics</i> , 2020, 30, 131-144.	1.5	26
35	Predictive response biomarkers in rectal cancer neoadjuvant treatment. <i>Frontiers in Bioscience - Scholar</i> , 2014, S6, 110-119.	2.1	26
36	Genetic biomarkers for hepatocellular cancer risk in a caucasian population. <i>World Journal of Gastroenterology</i> , 2017, 23, 6674-6684.	3.3	26

#	ARTICLE	IF	CITATIONS
37	New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach. <i>Cells</i> , 2019, 8, 584.	4.1	25
38	miRNA pharmacogenomics: the new frontier for personalized medicine in cancer?. <i>Pharmacogenomics</i> , 2012, 13, 1635-1650.	1.3	24
39	Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients. <i>Frontiers in Pharmacology</i> , 2018, 9, 367.	3.5	24
40	Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1522.	4.1	23
41	Circulating-Free DNA Analysis in Hepatocellular Carcinoma: A Promising Strategy to Improve Patientsâ€™ Management and Therapy Outcomes. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5498.	4.1	23
42	Germline variability and tumor expression level of ribosomal protein gene RPL28 are associated with survival of metastatic colorectal cancer patients. <i>Scientific Reports</i> , 2019, 9, 13008.	3.3	23
43	Improved Progression-Free Survival in Irinotecan-Treated Metastatic Colorectal Cancer Patients Carrying the HNF1A Coding Variant p.I27L. <i>Frontiers in Pharmacology</i> , 2017, 8, 712.	3.5	22
44	A Pharmacogenetic Survey of Androgen Receptor (CAG) _n and (GGN) _n Polymorphisms in Patients Experiencing Long Term Side Effects after Finasteride Discontinuation. <i>International Journal of Biological Markers</i> , 2014, 29, 310-316.	1.8	21
45	Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy. <i>Cell Death and Disease</i> , 2022, 13, 398.	6.3	20
46	Pharmacogenomics decision support in the U-PGx project: Results and advice from clinical implementation across seven European countries. <i>PLoS ONE</i> , 2022, 17, e0268534.	2.5	20
47	A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patients. <i>Pharmacogenomics Journal</i> , 2015, 15, 513-520.	2.0	19
48	UGT1A1*28 polymorphism in ovarian cancer patients. <i>Oncology Reports</i> , 2004, 12, 457-62.	2.6	19
49	MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin. <i>Pharmacogenomics Journal</i> , 2015, 15, 219-225.	2.0	18
50	Association of the <i>HLA</i>-3â€™UTR polymorphisms with colorectal cancer in Italy: a first insight. <i>International Journal of Immunogenetics</i> , 2016, 43, 32-39.	1.8	18
51	UGT1A polymorphisms as genetic biomarkers for hepatocellular carcinoma risk in Caucasian population. <i>Liver International</i> , 2017, 37, 1345-1353.	3.9	18
52	Androgen Receptor (<i>AR</i>) Gene (CAG) _n and (GGN) _n Length Polymorphisms and Symptoms in Young Males With Long-Lasting Adverse Effects After Finasteride Use Against Androgenic Alopecia. <i>Sexual Medicine</i> , 2017, 5, e61-e71.	1.6	18
53	Methylenetetrahydrofolate reductase genotype in diffuse large B-cell lymphomas with and without hypermethylation of the DNA repair gene O6-methylguanine DNA methyltransferase. <i>International Journal of Biological Markers</i> , 2003, 18, 218-221.	1.8	18
54	BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress. <i>Cell Death and Disease</i> , 2016, 7, e2374-e2374.	6.3	16

#	ARTICLE	IF	CITATIONS
55	Pharmacogenetics and stomach cancer: an update. <i>Pharmacogenomics</i> , 2007, 8, 497-505.	1.3	15
56	Decision criteria for rational selection of homogeneous genotyping platforms for pharmacogenomics testing in clinical diagnostics. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 447-59.	2.3	15
57	Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers. <i>European Journal of Cancer</i> , 2018, 104, 210-218.	2.8	14
58	Educating the Next Generation of Pharmacogenomics Experts: Global Educational Needs and Concepts. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 313-316.	4.7	14
59	Germline Polymorphisms in the Nuclear Receptors PXR and VDR as Novel Prognostic Markers in Metastatic Colorectal Cancer Patients Treated With FOLFIRI. <i>Frontiers in Oncology</i> , 2019, 9, 1312.	2.8	14
60	Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. <i>Oncotarget</i> , 2016, 7, 19781-19793.	1.8	14
61	HLA-G 3'UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1366.	4.1	13
62	Azathioprine Biotransformation in Young Patients with Inflammatory Bowel Disease: Contribution of Glutathione-S Transferase M1 and A1 Variants. <i>Genes</i> , 2019, 10, 277.	2.4	13
63	Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1482.	4.1	12
64	Genetic Variants of the TERT Gene, Telomere Length, and Circulating TERT as Prognostic Markers in Rectal Cancer Patients. <i>Cancers</i> , 2020, 12, 3115.	3.7	12
65	Genetic Markers of the Host to Predict the Efficacy of Colorectal Cancer Targeted Therapy. <i>Current Medicinal Chemistry</i> , 2020, 27, 4249-4273.	2.4	11
66	Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS). <i>International Journal of Molecular Sciences</i> , 2018, 19, 1510.	4.1	10
67	Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC). <i>Cells</i> , 2019, 8, 1186.	4.1	10
68	Clonal Selection of a Novel Deleterious TP53 Somatic Mutation Discovered in ctDNA of a KIT/PDGFR Wild-Type Gastrointestinal Stromal Tumor Resistant to Imatinib. <i>Frontiers in Pharmacology</i> , 2020, 11, 36.	3.5	10
69	Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy. <i>Frontiers in Pharmacology</i> , 2020, 11, 897.	3.5	10
70	IL15RA and SMAD3 Genetic Variants Predict Overall Survival in Metastatic Colorectal Cancer Patients Treated with FOLFIRI Therapy: A New Paradigm. <i>Cancers</i> , 2021, 13, 1705.	3.7	10
71	FARMAPRICE: A Pharmacogenetic Clinical Decision Support System for Precise and Cost-Effective Therapy. <i>Genes</i> , 2019, 10, 276.	2.4	9
72	A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study. <i>Clinical Breast Cancer</i> , 2019, 19, 137-145.e4.	2.4	9

#	ARTICLE	IF	CITATIONS
73	Impact of DNA repair gene polymorphisms on the risk of biochemical recurrence after radiotherapy and overall survival in prostate cancer. <i>Oncotarget</i> , 2017, 8, 22863-22875.	1.8	9
74	UGT1A1*28 polymorphism in ovarian cancer patients. <i>Oncology Reports</i> , 0, , .	2.6	9
75	A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy. <i>Frontiers in Pharmacology</i> , 2018, 9, 1101.	3.5	8
76	Focal Recurrent Copy Number Alterations Characterize Disease Relapse in High Grade Serous Ovarian Cancer Patients with Good Clinical Prognosis: A Pilot Study. <i>Genes</i> , 2019, 10, 678.	2.4	8
77	miR-331-3p is involved in glucocorticoid resistance reversion by rapamycin through suppression of the MAPK signaling pathway. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 361-374.	2.3	7
78	Pharmacogenomics and stomach cancer. <i>Pharmacogenomics</i> , 2004, 5, 627-641.	1.3	6
79	Combination of germline variations associated with survival of folinic acid, fluorouracil and irinotecan-treated metastatic colorectal cancer patients. <i>Pharmacogenomics</i> , 2019, 20, 1179-1187.	1.3	6
80	rs4143815-PDL1, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2082.	4.1	6
81	Immunogenetic markers in IL17F predict the risk of metastases spread and overall survival in rectal cancer patients treated with neoadjuvant chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 149, 30-37.	0.6	6
82	Clinical implications of genetic polymorphisms on stomach cancer drug therapy. <i>Pharmacogenomics Journal</i> , 2007, 7, 76-80.	2.0	5
83	A TGF- β 2 associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 156, 233-242.	1.4	5
84	Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients. <i>AAPS Journal</i> , 2020, 22, 59.	4.4	4
85	SMAD3 Host and Tumor Profiling to Identify Locally Advanced Rectal Cancer Patients at High Risk of Poor Response to Neoadjuvant Chemoradiotherapy. <i>Frontiers in Pharmacology</i> , 2021, 12, 778781.	3.5	4
86	The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines. , 2019, 2, 116-130.		3
87	Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer. <i>Pharmacogenomics</i> , 2020, 21, 995-1010.	1.3	2
88	Improving decision making on DPYD and UGT1A1*28 patients' profiling with an innovative reimbursement strategy. <i>Pharmacogenomics</i> , 2018, 19, 301-304.	1.3	1
89	Pharmacogenetics in Cancer Management: Scenario for Tailored Therapy. , 2008, , 389-403.		1
90	Abstract 3889: RPL28 promoter polymorphism rs4806668 is associated with reduced survival in FOLFIRI-treated metastatic colorectal cancer patients. <i>Cancer Research</i> , 2018, 78, 3889-3889.	0.9	1

#	ARTICLE	IF	CITATIONS
91	Pharmacogenetics of stomach cancer. I Supplementi Di Tumori, 2003, 2, S19-22.	0.1	1
92	Predicting drug response and toxicity in metastatic colorectal cancer: the role of germline markers. Expert Review of Clinical Pharmacology, 2022, 15, 689-713.	3.1	1
93	Reply to the Letter to the Editor from Chowbay et al. Clinical Cancer Research, 2006, 12, 1942.2-1942.	7.0	0
94	RPL28 Promoter polymorphism RS4806668 is associated with reduced survival in folfiri-treated metastatic colorectal cancer patients. Drug Metabolism and Pharmacokinetics, 2019, 34, S64-S65.	2.2	0
95	Abstract 4841: GSTM1 and GSTT1 polymorphisms in population-based study of colorectal cancer risk.. , 2013, , .		0